Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1997019183) TISSUE-SPECIFIC TRANSCRIPTION OF DNA SEQUENCE ENCODING A HETEROLOGOUS ENZYME FOR USE IN PRODRUG THERAPY TO LUNG CANCER
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1997/019183 International Application No.: PCT/GB1996/002846
Publication Date: 29.05.1997 International Filing Date: 19.11.1996
Chapter 2 Demand Filed: 06.06.1997
IPC:
A61K 38/00 (2006.01) ,A61K 47/48 (2006.01) ,A61K 48/00 (2006.01) ,C07K 14/47 (2006.01) ,C07K 14/575 (2006.01) ,C07K 14/665 (2006.01) ,C07K 14/785 (2006.01) ,C12N 9/86 (2006.01) ,C12N 15/85 (2006.01) ,C12N 15/867 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
48
the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
46
from vertebrates
47
from mammals
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
575
Hormones
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
665
derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
785
Alveolar surfactant peptides; Pulmonary surfactant peptides
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9
Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14
Hydrolases (3.)
78
acting on carbon to nitrogen bonds other than peptide bonds (3.5)
86
acting on amide bonds in cyclic amides, e.g. penicillinase
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
63
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79
Vectors or expression systems specially adapted for eukaryotic hosts
85
for animal cells
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
63
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79
Vectors or expression systems specially adapted for eukaryotic hosts
85
for animal cells
86
Viral vectors
867
Retroviral vectors
Applicants:
GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House Berkeley Avenue Greenford Middlesex UB6 0NN, GB (AllExceptUS)
DEV, Inderjit [US/US]; US (UsOnly)
MOORE, John, Tomlin [US/US]; US (UsOnly)
SETHNA, Phiroze, Behram [IN/US]; US (UsOnly)
Inventors:
DEV, Inderjit; US
MOORE, John, Tomlin; US
SETHNA, Phiroze, Behram; US
Agent:
REES, Marion; Glaxo Wellcome plc Glaxo Wellcome House, Berkeley Avenue Greenford, Middlesex UB6 0NN, GB
Priority Data:
9523703.820.11.1995GB
Title (EN) TISSUE-SPECIFIC TRANSCRIPTION OF DNA SEQUENCE ENCODING A HETEROLOGOUS ENZYME FOR USE IN PRODRUG THERAPY TO LUNG CANCER
(FR) TRANSCRIPTION SPECIFIQUE POUR LE TISSU D'UNE SEQUENCE D'ADN CODANT UNE ENZYME HETEROLOGUE CONNUE POUR ETRE UTILISEE DANS UNE THERAPIE A BASE D'UN PROMEDICAMENT ENZYMATIQUE POUR TRAITER LE CANCER DU POUMON
Abstract:
(EN) The invention relates to the use of a molecular chimaera with a prodrug in the therapy of lung cancer, the molecular chimaera comprising a transcriptional regulatory DNA sequence derived from a gene encoding a lung-associated protein or a neuroendocrine marker protein and, operatively linked to the transcriptional regulatory DNA sequence, DNA sequence encoding a heterologous enzyme capable of catalysing the conversion of the prodrug into an agent toxic to a lung cancer cell. The use of lung specific promoters in a GDEPT or VDEPT approach allows specific targetting of lung cancer cells.
(FR) L'invention concerne l'utilisation de chimères moléculaires avec un promédicament dans la thérapie du cancer du poumon, ces chimères moléculaires comprenant une séquence d'ADN de régulation de transcription dérivée d'un gène codant une protéine associée aux poumons ou une protéine de marqueur de neuroendocrine et, reliée à ladite séquence d'ADN de régulation de transcription, une séquence d'ADN codant une enzyme hétérologue capable de catalyser la conversion du promédicament en un agent toxique pour la cellule cancéreuse du poumon. L'utilisation de promoteurs spécifiques pour le poumon dans un contexte de GDEPT ou VDEPT, permet de réaliser un ciblage spécifique des cellules cancéreuses du poumon.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN
African Regional Intellectual Property Organization (ARIPO) (KE, LS, MW, SD, SZ, UG)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
AU1996077004